Loading…
Zoledronic Acid Medac is a brand name for Zoledronic Acid. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. - Treatment of adult patients with tumour-induced hypercalcaemia (TIH).
Verbatim from this product's EMA label. Tap a section to expand.
Zoledronic acid medac must only be prescribed and administered to patients by healthcare professionals experienced in the administration of intravenous bisphosphonates. Patients treated with Zoledronic acid medac should be given the package leaflet and the patient reminder card.
Posology Prevention of skeletal related events in patients with advanced malignancies involving bone Adults and elderly people The recommended dose in the prevention of skeletal related events in patients with advanced malignancies involving bone is 4 mg zoledronic acid every 3 to 4 weeks.
Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily. The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2-3 months.
0 mmol/l) is a single dose of 4 mg zoledronic acid.
Medicinal product no longer authorised 3 Renal impairment TIH:
Zoledronic acid treatment in TIH patients who also have severe renal impairment should be considered only after evaluating the risks and benefits of treatment. 5 mg/dl were excluded. 4). Prevention of skeletal related events in patients with advanced malignancies involving bone: When initiating treatment with zoledronic acid in patients with multiple myeloma or metastatic bone lesions from solid tumours, serum creatinine and creatinine clearance (CLcr) should be determined.
CLcr is calculated from serum creatinine using the Cockcroft-Gault formula. Zoledronic acid is not recommended for patients presenting with severe renal impairment prior to initiation of therapy, which is defined for this population as CLcr < 30 ml/min.
0 mg/dl were excluded. For patients with normal renal function (defined as CLcr > 60 ml/min), zoledronic acid 4 mg/100 ml solution for infusion may be administered directly without any further preparation. 66 (mg•hr/l) (CLcr=75 ml/min).
The reduced doses for patients with renal impairment are expected to achieve the same AUC as that seen in patients with creatinine clearance of 75 ml/min. Following initiation of therapy, serum creatinine should be measured prior to each dose of zoledronic acid and treatment should be withheld if renal function has deteriorated.
Summary of the safety profile Medicinal product no longer authorised 8 Within three days after zoledronic acid administration, an acute phase reaction has been reported, with symptoms including bone pain, fever, fatigue, arthralgia, myalgia, rigors and arthritis with subsequent joint swelling; these symptoms usually resolve within a few days (see description of selected adverse reactions).
The following are the important identified risks with zoledronic acid in the approved indications: Renal function impairment, osteonecrosis of the jaw, acute phase reaction, hypocalcaemia, atrial fibrillation, anaphylaxis, interstitial lung disease.
The frequencies for each of these identified risks are shown in Table 2. Tabulated list of adverse reactions The following adverse reactions, listed in Table 2, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid: Table 2 Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).
Blood and lymphatic system disorders Common:
Uncommon: Rare: Anaemia Thrombocytopenia, leukocytopenia Pancytopenia Immune system disorders Uncommon: Rare: Hypersensitivity reaction Angioneurotic oedema Psychiatric disorders Uncommon: Rare: Anxiety, sleep disturbance Confusion Nervous system disorders Common: Uncommon: Very rare: Headache Dizziness, paraesthesia, dysgeusia, hypoaesthesia, hyperaesthesia, tremor, somnolence Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia) Eye disorders Common: Uncommon: Rare: Very rare: Conjunctivitis Blurred vision, scleritis and orbital inflammation Uveitis Episcleritis Cardiac disorders Uncommon: Rare: Hypertension, hypotension, atrial fibrillation, hypotension leading to syncope or circulatory collapse Bradycardia, cardiac arrhythmia (secondary to hypocalcaemia) Respiratory, thoracic and mediastinal disorders Uncommon: Rare: Dyspnoea, cough, bronchoconstriction Interstitial lung disease Gastrointestinal disorders Common: Nausea, vomiting, decreased appetite Medicinal product no longer authorised 9 Uncommon: Diarrhoea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth Skin and subcutaneous tissue disorders Uncommon: Pruritus, rash (including erythematous and macular rash), increased sweating Musculoskeletal and connective tissue disorders Common: Uncommon: Very rare: Bone pain, myalgia, arthralgia, generalised pain Muscle spasms, osteonecrosis of the jaw Osteonecrosis of the external auditory canal (bisphosphonate class adverse reaction) and other anatomical sites including femur and hip Renal and urinary disorders Common: Uncommon: Rare: Not known: Renal impairment Acute renal failure, haematuria, proteinuria Acquired Fanconi syndrome Tubulointerstitial nephritis General disorders and administration site conditions Common: Uncommon: Rare: Fever, flu-like syndrome (including fatigue, rigors, malaise and flushing) Asthenia, peripheral oedema, injection site reactions (including pain, irritation, swelling, induration), chest pain, weight increase, anaphylactic reaction/shock, urticaria Arthritis and joint swelling as a symptom of acute phase reaction Investigations Very common: Common: Uncommon: Rare: Hypophosphataemia Blood creatinine and blood urea increased, hypocalcaemia Hypomagnesaemia, hypokalaemia Hyperkalaemia, hypernatraemia Description of selected adverse reactions Renal function impairment Zoledronic acid has been associated with reports of renal dysfunction.
General Patients must be assessed prior to administration of zoledronic acid to ensure that they are adequately hydrated. Overhydration should be avoided in patients at risk of cardiac failure. Standard hypercalcaemia-related metabolic parameters, such as serum levels of calcium, phosphate and magnesium, should be carefully monitored after initiating zoledronic acid therapy.
If hypocalcaemia, hypophosphataemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. Untreated hypercalcaemia patients generally have some degree of renal function impairment, therefore careful renal function monitoring should be considered.
Other medicinal products containing zoledronic acid as active substances are available for osteoporosis indications and treatment of Paget´s disease of the bone. Patients being treated with Zoledronic acid medac should not be treated with such medicinal products concomitantly or any other bisphosphonate, since the combined effects of these agents are unknown.
Renal insufficiency Patients with TIH and evidence of deterioration in renal function should be appropriately evaluated with consideration given as to whether the potential benefit of treatment with zoledronic acid outweighs the possible risk.
Medicinal product no longer authorised 5 The decision to treat patients with bone metastases for the prevention of skeletal related events should consider that the onset of treatment effect is 2 – 3 months. Zoledronic acid has been associated with reports of renal dysfunction.
Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid 4 mg and other bisphosphonates as well as use of other nephrotoxic medicinal products.
While the risk is reduced with a dose of 4 mg zoledronic acid administered over 15 minutes, deterioration in renal function may still occur. Renal deterioration, progression to renal failure and dialysis have been reported in patients after the initial dose or a single dose of 4 mg zoledronic acid.
1. 6).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Zoledronic Acid in European Union.
Know a brand we are missing in European Union? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
0 mg/dl or 88 μmol/l. 4). Zoledronic acid treatment should be resumed at the same dose as that prior to treatment interruption. Paediatric population The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established.
1 but no recommendation on a posology can be made. Method of administration Intravenous use. Zoledronic acid medac 4 mg/100 ml solution for infusion should be given as a single intravenous infusion in no less than 15 minutes. In patients with normal renal function, defined as CLcr > 60 ml/min, zoledronic acid 4 mg/100 ml solution for infusion must not be further diluted.
4). To prepare reduced doses for patients with baseline CLcr ≤ 60 ml/min, refer to Table 1 below. 9%) solution for injection, or 5% glucose solution for injection. 0 Zoledronic acid medac 4 mg/100 ml solution for infusion must not be mixed with other infusion solutions and should be administered as a single intravenous solution in a separate infusion line.
Patients must be maintained well hydrated prior to and following administration of zoledronic acid.
2%). Factors that may increase the potential for deterioration in renal function include dehydration, pre-existing renal impairment, multiple cycles of zoledronic acid or other bisphosphonates, as well as concomitant use of nephrotoxic medicinal products or using a shorter infusion time than currently recommended.
4). 4). Many of these patients were also receiving chemotherapy and corticosteroids and had signs of local infection including osteomyelitis. The majority of the reports refer to cancer patients following tooth extractions or other dental surgeries.
Medicinal product no longer authorised 10 Atrial fibrillation In one 3-year, randomised, double-blind controlled trial that evaluated the efficacy and safety of zoledronic acid 5 mg once yearly vs. 9 % (75 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively.
6 % (22 out of 3,852) in patients receiving zoledronic acid 5 mg and placebo, respectively. The imbalance observed in this trial has not been observed in other trials with zoledronic acid, including those with zoledronic acid 4 mg every 3 – 4 weeks in oncology patients.
The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is […]
Increases in serum creatinine also occur in some patients with chronic administration of zoledronic acid at recommended doses for prevention of skeletal related events, although less frequently. Patients should have their serum creatinine levels assessed prior to each dose of zoledronic acid.
Upon initiation of treatment in patients with bone metastases with mild to moderate renal impairment, lower doses of zoledronic acid are recommended. In patients who show evidence of renal deterioration during treatment, zoledronic acid should be withheld.
Zoledronic acid should only be resumed when serum creatinine returns to within 10 % of baseline. Zoledronic acid medac treatment should be resumed at the same dose as that given prior to treatment interruption. 0 mg/dl for patients with cancer and bone metastases, respectively) at baseline and only limited pharmacokinetic data in patients with severe renal impairment at baseline (creatinine clearance < 30 ml/min), the use of zoledronic acid is not recommended in patients with severe renal impairment.
Hepatic insufficiency As only limited clinical data are available in patients with severe hepatic insufficiency, no specific recommendations can be given for this patient population. Osteonecrosis Osteonecrosis of the jaw Osteonecrosis of the jaw (ONJ) has been reported uncommonly in clinical trials and in the post- marketing setting in patients receiving zoledronic acid.
Post-marketing experience and the literature suggest a greater frequency of reports of ONJ based on tumour type (advanced breast cancer, multiple myeloma). 1). The start of treatment or of a new course of treatment should be delayed in patients with unhealed open soft tissue lesions in the mouth except in medical emergency situations.
A dental examination with appropriate preventive dentistry and an individual benefit-risk assessment is recommended prior to treatment with bisphosphonates in patients with concomitant risk factors. The following risk factors should be considered when evaluating an individual’s risk of developing ONJ: • Potency of the bisphosphonate (higher risk for highly potent compounds), route of administration (higher risk for parenteral administration) and cumulative dose of bisphosphonate.
g. anaemia, coagulopathies, infection), smoking. 5), radiotherapy to neck and head, corticosteroids. g. tooth extractions) and poorly fitting dentures. Medicinal product no longer authorised 6 All patients should be encouraged to maintain good oral hygiene, undergo routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain or swelling, or non-healing of sores or discharge during treatment with Zoledronic acid medac.
While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to zoledronic acid administration. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition.
For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of osteonecrosis of the jaw. The management plan for patients who develop ONJ should be set up in close collaboration between the treating physician and a dentist or oral surgeon […]